Citius Oncology (CTOR) EBIT Margin (2025 - 2026)
Citius Oncology (CTOR) posted quarterly EBIT Margin of 1716.17% for Q1 2026, down 1188.73% quarter-over-quarter from 133.17% in Q4 2025.
Citius Oncology (CTOR) EBIT Margin (2025 - 2026) Analysis & Trends
Citius Oncology (CTOR) has reported EBIT Margin for 2 consecutive years, with 1716.17% the latest figure, recorded in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | -5.58% |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 33.91% |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 16.51% |
| 5 | United Therapeutics | 22.19 Bn | 19.53 Bn | 683.80 Mn | 42.23% |
| 6 | Viatris | 18.68 Bn | 17.79 Bn | 1.46 Bn | 0.17% |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 15.80% |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 18.13% |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | Citius Oncology | 79.84 Mn | 79.84 Mn | 1.00 Mn | -583.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,716.17% |
| Dec 31, 2025 | -133.17% |